

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptasxb1612

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS EXPRESS		FEBRUARY 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:18:30 ON 12 JUN 2008

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 11:18:39 ON 12 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jun 2008 VOL 148 ISS 24

FILE LAST UPDATED: 11 Jun 2008 (20080611/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> se 200721-95-5/rn

SE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s 200721-95-5/rn

4 200721-95-5

0 200721-95-5D

L1

4 200721-95-5/RN

(200721-95-5 (NOTL) 200721-95-5D)

=> d 1-4 ibib abs

L1 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1287775 CAPLUS

DOCUMENT NUMBER: 148:440629

TITLE: Physiological Testosterone Replacement Therapy Attenuates Fatty Streak Formation and Improves High-Density Lipoprotein Cholesterol in the Tfm Mouse: An effect that is independent of the classic androgen receptor

AUTHOR(S): Nettleship, Joanne E.; Jones, T. Hugh; Channer, Kevin S.; Jones, Richard D.
CORPORATE SOURCE: Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK
SOURCE: Circulation (2007), 116(21), 2427-2434
CODEN: CIRCAZ; ISSN: 0009-7322
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background- Research supports a beneficial effect of physiol. testosterone on cardiovascular disease. The mechanisms by which testosterone produces these effects have yet to be elucidated. The testicular feminized (Tfm) mouse exhibits a nonfunctional androgen receptor and low circulating testosterone concns. We used the Tfm mouse to determine whether testosterone modulates atheroma formation via its classic signaling pathway involving the nuclear androgen receptor, conversion to 17 β -estradiol, or an alternative signaling pathway. Methods and Results- Tfm mice (n = 31) and XY littermates (n = 8) were separated into 5 exptl. groups. Each group received saline (Tfm, n = 8; XY littermates, n = 8), physiol. testosterone alone (Tfm, n = 8), physiol. testosterone in conjunction with the estrogen receptor α antagonist fulvestrant (Tfm, n = 8), or physiol. testosterone in conjunction with the aromatase inhibitor anastrozole (Tfm, n = 7). All groups were fed a cholesterol-enriched diet for 28 wk. Serial sections from the aortic root were examined for fatty streak formation. Blood was collected for measurement of total cholesterol, high-d. lipoprotein cholesterol (HDLc), non-HDLc, testosterone, and 17 β -estradiol. Physiol. testosterone replacement significantly reduced fatty streak formation in Tfm mice compared with placebo-treated controls ($0.37 \pm 0.07\%$ vs. $2.86 \pm 0.39\%$, resp.; $P \leq 0.0001$). HDLc concns. also were significantly raised in Tfm mice receiving physiol. testosterone replacement compared with those receiving placebo (2.81 ± 0.30 vs. 2.08 ± 0.09 mmol/L, resp.; $P = 0.05$). Cotreatment with either fulvestrant or anastrozole completely abolished the improvement in HDLc. Conclusion- Physiol. testosterone replacement inhibited fatty streak formation in the Tfm mouse, an effect that was independent of the androgen receptor. The observed increase in HDLc is consistent with conversion to 17 β -estradiol.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:105398 CAPLUS

DOCUMENT NUMBER: 144:404555

TITLE: Physiologic Testosterone Therapy has no Effect on Serum Levels of Tumour Necrosis Factor- α in Men with Chronic Heart Failure

AUTHOR(S): Pugh, Peter J.; Jones, Richard D.; Malkin, Chris J.; Hall, Joanne; Nettleship, Joanne E.; Kerry, Katherine E.; Hugh Jones, T.; Channer, Kevin S.

CORPORATE SOURCE: Department of Cardiology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust, and Hormone & Vascular Biology Group, Academic Unit of Endocrinology, Division of Genomic Medicine, The University of Sheffield, Sheffield, UK

SOURCE: Endocrine Research (2005), 31(4), 271-283

CODEN: ENRSE8; ISSN: 0743-5800

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Physiol. testosterone therapy increases exercise capacity and reduces symptom scores in men with chronic heart failure (CHF). Tumor necrosis factor- α (TNF- α) exerts a significant pathol. activity in CHF,

and physiol. testosterone replacement therapy is associated with reduced serum levels of TNF- α in hypogonadal men with concomitant coronary artery disease. It is unknown whether testosterone exerts a similar immunomodulatory action in men with CHF. Consequently, serum levels of TNF- α were measured in men with CHF, before and after physiol. testosterone therapy administered in three placebo-controlled studies, for either 6 h (two 30-mg buccal tablets, n = 12) or 3 mo (fortnightly 100 mg intra muscular injection, n = 20; or daily 5 mg transdermally, n = 62). The effects of testosterone were also assessed on lipopolysaccharide (LPS)-induced TNF- α production in whole blood obtained from 27 men with CHF. Incubation with testosterone (10 nM, 1 μ M, and 100 μ M) resulted in a reduction in LPS-induced TNF- α production from 12.6 ± 1.3 to 11.2 ± 1.1 (P = 0.053), 10.3 ± 1.1 (P = 0.0046), and 9.2 ± 1.1 (P = 0.000066) ng/mL, resp. However in men with CHF, serum levels of TNF- α were similar before and after treatment with testosterone or placebo, irresp. of the length of study or route of administration. The clin. beneficial actions of testosterone in men with CHF are unlikely to be mediated by reducing TNF- α .

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:573327 CAPLUS

DOCUMENT NUMBER: 141:117443

TITLE: The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men

AUTHOR(S): Malkin, Chris J.; Pugh, Peter J.; Jones, Richard D.; Kapoor, Dheeraj; Channer, Kevin S.; Jones, T. Hugh

CORPORATE SOURCE: Department of Cardiology, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK

SOURCE: Journal of Clinical Endocrinology and Metabolism (2004), 89(7), 3313-3318

CODEN: JCEMAZ; ISSN: 0021-972X

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Testosterone has immune-modulating properties, and current in vitro evidence suggests that testosterone may suppress the expression of the proinflammatory cytokines TNF α , IL-1 β , and IL-6 and potentiate the expression of the antiinflammatory cytokine IL-10. We report a randomized, single-blind, placebo-controlled, crossover study of testosterone replacement (Sustanon 100) vs. placebo in 27 men (age, 62 ± 9 yr) with symptomatic androgen deficiency (total testosterone, 4.4 ± 1.2 nmol/L; bioavailable testosterone, 2.4 ± 1.1 nmol/L). Compared with placebo, testosterone induced redns. in TNF α (-3.1 ± 8.3 vs. 1.3 ± 5.2 pg/mL; P = 0.01) and IL-1 β (-0.14 ± 0.32 vs. 0.18 ± 0.55 pg/mL; P = 0.08) and an increase in IL-10 (0.33 ± 1.8 vs. -1.1 ± 3.0 pg/mL; P = 0.01); the redns. of TNF α and IL-1 β were pos. correlated (rS = 0.588; P = 0.003). In addition, a significant reduction in total cholesterol was recorded with testosterone therapy (-0.25 ± 0.4 vs. -0.004 ± 0.4 mmol/L; P = 0.04). In conclusion, testosterone replacement shifts the cytokine balance to a state of reduced inflammation and lowers total cholesterol. Twenty of these men had established coronary disease, and because total cholesterol is a cardiovascular risk factor, and proinflammatory cytokines mediate the development and complications associated with atheromatous plaque, these properties may have particular relevance in men with overt vascular disease.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:767377 CAPLUS
 DOCUMENT NUMBER: 128:71699
 TITLE: Black market in anabolic steroids-analysis of
 illegally distributed products
 AUTHOR(S): Musshoff, Frank; Daldrup, Thomas; Ritsch, Mathias
 CORPORATE SOURCE: Institute of Legal Medicine, Rheinische
 Friedrich-Wilhelms-University, Bonn, Germany
 SOURCE: Journal of Forensic Sciences (1997), 42(6), 1119-1125
 CODEN: JFSCAS; ISSN: 0022-1198
 PUBLISHER: American Society for Testing and Materials
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Anabolic steroids found in the illegal market often do not contain
 ingredients declared on the label. Forty-two products encountered in the
 illegal distribution channels were analyzed by gas chromatog./mass
 spectrometry. Fifteen of the products did not contain the expected
 ingredients. Mainly, counterfeits of parabolane and primobolan products
 were found. Instead of trenbolone or metenolone, the cheaper agents
 nandrolone or testosterone derivs. were identified. In one product the
 gestagene progesterone was found. In two other cases no steroid was
 present or tocopherol was substituted.
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	17.32	17.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 11:20:42 ON 12 JUN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptasxb1612

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats

NEWS 5 JAN 28 MARPAT searching enhanced
 NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
 of publication
 NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 9 FEB 08 STN Express, Version 8.3, now available
 NEWS 10 FEB 20 PCI now available as a replacement to DPCI
 NEWS 11 FEB 25 IFIREF reloaded with enhancements
 NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
 NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
 U.S. National Patent Classification
 NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
 IPC display formats
 NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
 spectra
 NEWS 16 MAR 31 CA/CAPplus and CASREACT patent number format for U.S.
 applications updated
 NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
 NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
 NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
 predefined hit display formats
 NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
 NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
 NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family
 searching
 NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
 sequence search option
 NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts
 NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents
 NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character
 patent numbers for U.S. applications

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:01:36 ON 17 JUN 2008

=>

=> file registry

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:01:48 ON 17 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUN 2008 HIGHEST RN 1028528-04-2
DICTIONARY FILE UPDATES: 16 JUN 2008 HIGHEST RN 1028528-04-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 1255-49-8/rn

L1 1 1255-49-8/RN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 1255-49-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Androst-4-en-3-one, 17-(1-oxo-3-phenylpropoxy)-, (17 β)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Hydrocinnamic acid, ester with testosterone (8CI)

CN Testosterone, hydrocinnamate (6CI, 7CI, 8CI)

OTHER NAMES:

CN 3-Oxoandrost-4-en-17 β -yl β -phenylpropionate

CN Androject

CN Hydrocinnamic acid, testosterone ester

CN NSC 26643

CN Retandrol

CN Testosterone 17-phenylpropionate

CN Testosterone phenpropionate

CN Testosterone phenylpropionate

FS STEREOSEARCH

MF C28 H36 O3


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, RTECS*, SPECINFO, TOXCENTER, USPATFULL, USPATOLD, VETU
(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

182 REFERENCES IN FILE CA (1907 TO DATE)
 184 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 26 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus
 COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
2.92	3.13

FILE 'CAPLUS' ENTERED AT 14:03:17 ON 17 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jun 2008 VOL 148 ISS 25
 FILE LAST UPDATED: 16 Jun 2008 (20080616/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l1

L2 184 L1

=> s l1/uses

184 L1
 7059433 USES/RL


L3 7 L1/USES

(L1 (L) USES/RL)

=> d 1-7 ibib abs

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:328158 CAPLUS
DOCUMENT NUMBER: 147:427591
TITLE: A transdermal gel/cream composition containing testosterone derivatives for transdermal delivery system
INVENTOR(S): Goyal, Prabhat; Sadvilkar, Vikas; Vishwanathan, Kannan; Bulut, Mark; Bulut, Steve
PATENT ASSIGNEE(S): Benzochem Lifesciences (P) Ltd., India
SOURCE: Indian Pat. Appl., 15pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
IN 2005MU00019	A	20060224	IN 2005-MU19	20050107
PRIORITY APPLN. INFO.: GI			IN 2005-MU19	20050107



AB A transdermal gel/cream composition containing testosterone derivs. I [R = propionate, cypionate, enanthioate, decanoate, phenylpropionate, isocaproate] for transdermal delivery system, comprising a formula comprising an active ingredient, gelling agents, permeation enhancers along with solvent using water.

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:890398 CAPLUS
DOCUMENT NUMBER: 145:298800
TITLE: Film forming foamable pharmaceutical and cosmetic compositions and cosmetic and therapeutic uses thereof
INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir
PATENT ASSIGNEE(S): Foamix Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 20pp., Cont.-in-part of U.S. Ser. No. 922,358.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 26
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20060193789	A1	20060831	US 2006-337747	20060123
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050069566 A1 20050331 US 2004-911367 20040804
 US 20050074414 A1 20050407 US 2004-922358 20040820
 ZA 2005003298 A 20060830 ZA 2005-3298 20050425
 AU 2006201878 A1 20070927 AU 2006-201878 20060504

PRIORITY APPLN. INFO.:

IL 2002-152486 A 20021025
 US 2002-429546P P 20021129
 US 2003-492385P P 20030804
 US 2003-497648P P 20030825
 WO 2003-IB5527 A2 20031024
 US 2004-911367 A2 20040804
 US 2004-922358 A2 20040820

AB The present invention provides a film-forming foamable cosmetic or pharmaceutical vehicle, and cosmetic and/or pharmaceutical compns. thereof. Specifically, the foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alc. free and is used in treating, alleviating or preventing a disorder.

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:75083 CAPLUS
 DOCUMENT NUMBER: 144:177461
 TITLE: Steroid kit and foamable composition
 INVENTOR(S): Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir
 PATENT ASSIGNEE(S): Foamix Ltd., Israel
 SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 911,367.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 26
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20060018937	A1	20060126	US 2005-114410	20050426
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050069566	A1	20050331	US 2004-911367	20040804

ZA 2005003298	A	20060830	ZA 2005-3298	20050425
AU 2006273697	A1	20070201	AU 2006-273697	20060418
CA 2606933	A1	20070201	CA 2006-2606933	20060418
WO 2007012977	A2	20070201	WO 2006-IB2832	20060418
WO 2007012977	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1890679	A2	20080227	EP 2006-795585	20060418
------------	----	----------	----------------	----------

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

FR 2884713	A1	20061027	FR 2006-51492	20060426
------------	----	----------	---------------	----------

AU 2006201878	A1	20070927	AU 2006-201878	20060504
---------------	----	----------	----------------	----------

IN 2007KN04205	A	20080606	IN 2007-KN4205	20071101
----------------	---	----------	----------------	----------

PRIORITY APPLN. INFO.:

IL 2002-152486	A	20021025
----------------	---	----------

US 2002-429546P	P	20021129
-----------------	---	----------

US 2003-492385P	P	20030804
-----------------	---	----------

WO 2003-IB5527	W	20031024
----------------	---	----------

US 2004-911367	A2	20040804
----------------	----	----------

US 2005-114410	A	20050426
----------------	---	----------

WO 2006-IB2832	W	20060418
----------------	---	----------

AB A composition and therapeutic kit includes an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a steroid as a foam. The pressurized product includes a foamable composition including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a steroid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixts. thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition

The composition further may include a therapeutically active foam adjuvant, selected from the group consisting of a fatty alc., a fatty acid, a hydroxyl fatty acid; and mixts. thereof. A composition contained hydrocortisone propionate, mineral oil, iso-Pr myristate, glyceryl monostearate, stearyl alc. Xanthan gum, Methocel K100M, Polysorbate 80, PEG-40 stearate, di-Na EDTA, preservative, propellant, and water.

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:303502 CAPLUS

DOCUMENT NUMBER: 142:341484

TITLE: Topical skin preparations comprising a testosterone ester and uses for treatment of skin atrophy and aging

INVENTOR(S): Dikstein, Shabtay

PATENT ASSIGNEE(S): Topimed Ltd., Israel

SOURCE: PCT Int. Appl., 15 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030159	A1	20050407	WO 2004-IL747	20040816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536402	A1	20050407	CA 2004-2536402	20040816
EP 1656100	A1	20060517	EP 2004-745084	20040816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20060292185	A1	20061228	US 2006-568275	20060504
PRIORITY APPLN. INFO.:			IL 2003-157535	A 20030821
			WO 2004-IL747	W 20040816
AB The present invention concerns topical skin prepsns. for the use in the prevention of atrophy and aging of the skin, comprising a testosterone ester with an esterifying acid having between six to eleven carbon atoms.				
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:745946 CAPLUS
 DOCUMENT NUMBER: 128:16440
 ORIGINAL REFERENCE NO.: 128:3115a,3118a
 TITLE: Topical penile androgen application for treatment of erectile dysfunction
 INVENTOR(S): Klippel, Karl-Friedrich; Hiltl, Dirk-Michael
 PATENT ASSIGNEE(S): Azupharma G.m.b.H., Germany; Klippel, Karl-Friedrich; Hiltl, Dirk-Michael
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741865	A1	19971113	WO 1997-DE863	19970428
W: US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 952833	A1	19991103	EP 1997-923761	19970428
R: DE				
PRIORITY APPLN. INFO.:			DE 1996-19617451	A 19960502
			WO 1997-DE863	W 19970428
AB Erectile dysfunction is treated by topical, preferably glandular-subpreputial or intraglandular-intraurethral, application of an androgen on the penis. Thus, a topical cream contained testosterone propionate 0.85, cetyl stearyl alc. 16.00, medium-chain triglycerides				

10.00, sorbic acid 0.10, K sorbate 0.10, propylene glycol 4.00, perfume oil 0.02, citric acid 0.01, and H2O 68.92 g.

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:494069 CAPLUS
DOCUMENT NUMBER: 127:145990
ORIGINAL REFERENCE NO.: 127:28093a,28096a
TITLE: Electrospray mass spectrometry of testosterone esters:
potential for use in doping control
AUTHOR(S): Shackleton, Cedric H.L.; Chuang, Hans; Kim, John; De
La Torre, Xavier; Segura, Jordi
CORPORATE SOURCE: Children's Hospital Oakland Research Institute,
Oakland, CA, 94609, USA
SOURCE: Steroids (1997), 62(7), 523-529
CODEN: STEDAM; ISSN: 0039-128X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The study described involves an attempt to identify 17 β -fatty acid esters of testosterone in blood plasma following administration of such agents. These drugs are therapeutic but are increasingly misused by athletes in an attempt to improve sports performance. The mass spectral properties of testosterone esters under electrospray ionization are described. These esters (testosterone acetate, propionate, isocaproate, benzoate, enanthate, cypionate, phenylpropionate, decanoate, and undecanoate) essentially give only a protonated mol. ion (MH⁺) under "optimum sensitivity" mass spectrometric conditions but could be induced to fragment in the source or collision cell of a triple quadrupole mass spectrometer. The underivatized steroid esters were analyzed by direct infusion because development of solvent systems compatible with high-performance liquid chromatog. (HPLC) was not achieved for these nonpolar compds. HPLC/MS (mass spectrometry) was possible when the steroids were converted to polar, water soluble, Girard hydrazones, and almost all compds. were separated by microbore C4 HPLC using a water, acetonitrile, TFA gradient. The mass spectra under optimal ionization conditions essentially comprised only a mol. ion (M⁺), but source fragmentation gave major ions at M - 59 and M - 87 for all compds. The mol. ion and these fragment ions were monitored in a selected-ion-recording (SIR) method developed for detecting the steroids in plasma. Using this methodol., testosterone enanthate and undecanoate could be detected after i.m. injection or oral administration of the drugs. Further development of the technique could form the basis of a protocol for confirming the misuse of testosterone in sport, especially if sensitivity could be improved.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:404059 CAPLUS
DOCUMENT NUMBER: 125:76786
ORIGINAL REFERENCE NO.: 125:14391a,14394a
TITLE: Testosterone therapy in glucocorticoid-treated men
AUTHOR(S): Reid, Ian R.; Wattie, Diana J.; Evans, Margaret C.;
Stapleton, Joanne P.
CORPORATE SOURCE: Department of Medicine, University of Auckland, N. Z.
SOURCE: Archives of Internal Medicine (1996), 156(11),
1173-1177
CODEN: AIMDAP; ISSN: 0003-9926
PUBLISHER: American Medical Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Treatment with glucocorticoid drugs is a valuable therapy, but the use of

these drugs is associated with major side effects, including osteoporosis, muscle wasting, and obesity. In men who take glucocorticoids, circulating testosterone concns. are reduced, and this might contribute to the changes in bone and soft-tissue mass. To assess the effect of testosterone replacement on these above-mentioned parameters, asthmatic men who were receiving long-term glucocorticoid treatment were randomly allocated to receive therapy with testosterone esters (30 mg of propionate, 60 mg of phenylpropionate, 60 mg of isocaproate, and 100 mg of decanoate [Sustanon]) (250 mg/mo i.m. depot injection) or to act as control subjects during 12 mo. After a washout period for those men who were receiving testosterone, the groups were then crossed over and studied for a further 12 mo. Bone d. and body composition were assessed by dual-energy, x-ray absorptiometry. Bone d. in the lumbar spine increased 5.0% during testosterone supplementation, but it did not change during the control period. These changes were accompanied by a decrease in the indexes of bone turnover. There was a gain in body fat mass (2.1 kg) and a loss of lean body mass (1.4 kg) during the control period, with both changes being reversed by testosterone treatment. Thus, testosterone treatment reverses the deleterious effects of glucocorticoid drugs on skeletal and soft tissues in men.

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
26.81	29.94

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.60	-5.60

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:08:23 ON 17 JUN 2008